ESMR, or extracorporeal shockwave myocardial revascularization, is a noninvasive heart treatment that uses low-energy sound waves to stimulate new blood vessel growth in areas of the heart that aren’t getting enough blood flow. It’s designed for people with chronic chest pain (angina) who can’t undergo bypass surgery or stenting and haven’t found relief from medications alone. The treatment requires no anesthesia, no incisions, and no hospital stay.
How Shockwave Therapy Grows New Blood Vessels
The treatment works by directing focused, low-intensity shockwaves at the heart muscle. These waves cause microscopic bubbles in tissue to collapse rapidly, creating tiny shear forces on the heart’s cells. That mechanical stress triggers the release of proteins that promote blood vessel growth, particularly vascular endothelial growth factor (VEGF) and nitric oxide. Both substances encourage new small blood vessels to sprout and existing ones to expand, gradually restoring blood supply to oxygen-starved regions of the heart.
Animal studies confirmed that shockwave-treated heart tissue shows higher concentrations of these growth-promoting substances. Over time, the improved blood flow leads to better heart muscle flexibility and remodeling, which translates to less chest pain during physical activity and daily life.
Who Is a Candidate for ESMR
ESMR is specifically intended for people with refractory angina, meaning chest pain that persists despite maximum medication therapy. To qualify, patients typically need to meet several criteria: a documented history of coronary artery disease, at least three months of ongoing angina symptoms, and a consensus from both an interventional cardiologist and a cardiac surgeon that neither bypass surgery nor stenting is a viable option. Medications must have been stable for at least six weeks before treatment begins.
Several conditions rule out the treatment. These include:
- Recent heart attack or unstable angina within the previous three months
- Active heart infections such as endocarditis, myocarditis, or pericarditis
- Moderate to severe valve disease or blood clots inside the heart
- Severe chronic lung disease including emphysema or pulmonary fibrosis
- Implanted cardiac devices such as pacemakers or defibrillators
- Inadequate acoustic window, meaning the ultrasound probe can’t get a clear enough view of the heart to guide treatment accurately
That last point is worth noting: because the shockwaves are aimed using real-time ultrasound imaging, the treatment simply can’t be performed safely if the operator can’t clearly visualize the target area through the chest wall.
What a Treatment Course Looks Like
A full ESMR course consists of nine sessions, each lasting about 20 minutes, spread over nine weeks. The sessions are grouped into three clusters: three sessions in week one, three in week five, and three in week nine. You lie on an examination table while a technician positions an ultrasound probe on your chest. The same probe that provides the image also delivers the shockwaves.
The shockwaves are timed to your heartbeat using an ECG trigger, firing only during a specific phase of the cardiac cycle to ensure safety. Energy levels are kept very low, in the range of 0.03 to 0.2 millijoules per square millimeter, with the focus area sized at roughly 8 to 9 millimeters wide and 25 millimeters long. That’s enough to cover the full thickness of the heart wall in the targeted zone. Before treatment begins, imaging (often a PET scan) maps out which areas of the heart are receiving inadequate blood flow, and the shockwave generator is aimed precisely at those regions.
How Well It Works
In a multicenter study published in the Journal of the American College of Cardiology, 74.1% of patients experienced an improvement in their angina severity score, and maximum exercise time increased significantly after treatment. For people who had been limited to short walks or light activity by chest pain, that improvement can meaningfully change daily life.
The benefits appear to last well beyond the treatment period. A study with the longest published follow-up (averaging nearly three years, with some patients tracked for over six years) found that average angina severity scores dropped from 2.78 to 1.44 on a four-point scale. That’s roughly equivalent to going from pain with mild exertion to pain only during strenuous activity. Nitroglycerin use dropped from 67% of patients to 21%, and the hospitalization rate fell from 40% to 18%. These results held across the entire follow-up period, suggesting the new blood vessel growth triggered by the therapy is durable rather than temporary.
How ESMR Compares to Other Options
For patients with refractory angina, the main alternatives to ESMR are enhanced external counterpulsation (EECP) and spinal cord stimulation (SCS). EECP uses inflatable cuffs on the legs to boost blood flow back to the heart, while SCS implants a small device near the spinal cord to interrupt pain signals.
A comparative study of 153 refractory angina patients found that both EECP and SCS reduced angina compared to medications alone, with benefits maintained at 12 months. EECP showed a slightly more effective reduction than SCS. ESMR offers a distinct advantage in treatment burden: nine sessions over nine weeks, compared to EECP’s typical 35 sessions over seven weeks. Spinal cord stimulation, meanwhile, requires a surgical implant. ESMR is the only one of the three that works by directly addressing the underlying blood supply problem rather than managing symptoms through other pathways.
Safety and Side Effects
ESMR has a favorable safety profile compared to invasive cardiac procedures. The energy levels used are a fraction of those in kidney stone lithotripsy, which uses the same basic shockwave technology but at much higher intensities. The treatment doesn’t damage heart tissue, and the ECG-gated timing prevents shockwaves from being delivered during vulnerable phases of the heartbeat that could disrupt rhythm.
Clinical trials have been designed with strict exclusion criteria partly to maintain this safety margin. Patients with implanted cardiac devices are excluded because the shockwaves could interfere with device function. Those with life expectancy under 12 months or active cancer in the treatment area are also excluded. Within the eligible patient population, published studies have not reported significant adverse events directly attributable to the shockwave treatment itself.